New York, July 25, 2023 (GLOBE NEWSWIRE) -- The global breast recurrence score test market stood at US$ 216.8 million in 2022 and is forecasted to expand at a CAGR of 9.2% from 2023 to 2033. Genomic ...

A new statistical tool that combines multiple clinical and pathologic factors with a patient's 21-gene Oncotype DX Breast Recurrence Score ® result provides more accurate estimates about that ...

Overall, 597 of 630 patients were analyzable—247 patients had stage II, and 350 had stage III colon cancer. The continuous Recurrence Score was significantly associated with RFI after adjustment for ...

Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Median follow-up for recurrence was 9.2 years. Twenty-six ...

The recurrence score based on the 21-gene breast-cancer assay has been clinically useful in predicting a chemotherapy benefit in hormone-receptor–positive, human epidermal growth factor receptor 2 ...

A retrospective study validates the Oncotype 21-gene breast recurrence score as a predictive biomarker of adjuvant chemotherapy benefit in women with estrogen receptor (ER)-positive/human epidermal ...

A new risk score can help predict which pancreatic cancer survivors are more likely to suffer a recurrence of their cancer, researchers said.

- Updated RxPONDER study analysis provides further evidence that the test identifies the majority of women with early-stage, node-positive breast cancer who can avoid chemotherapy "New findings ...

MADISON, Wis., April 28, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that recommended use of its Oncotype DX Breast Recurrence ...